BioXcel Therapeutics (BTAI) Free Cash Flow (2017 - 2026)

BioXcel Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$11.8 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 1.94% year-over-year to -$11.8 million in Q1 2026; TTM through Mar 2026 was -$57.4 million, a 13.54% increase from a year earlier, with the FY2025 full-year figure at -$57.6 million, up 20.01% from the prior year.
• Free Cash Flow grew to -$11.8 million in Q1 2026 per BTAI's latest filing, from -$14.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$11.8 million in Q1 2026 and bottomed at -$52.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$23.2 million (2024), against an average of -$25.4 million.
• Across the five-year window, Free Cash Flow plunged 97.94% in 2022 and soared 66.18% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$38.6 million in 2022, then soared by 30.48% to -$26.9 million in 2023, then soared by 44.87% to -$14.8 million in 2024, then advanced by 4.04% to -$14.2 million in 2025, then gained by 16.9% to -$11.8 million in 2026.
• Per Business Quant, the three latest BTAI Free Cash Flow figures stand at -$11.8 million (Q1 2026), -$14.2 million (Q4 2025), and -$18.8 million (Q3 2025).